ArticleBMC geriatrics2025
Global epidemiological trend of cancer incidence and death in adults aged 60 years and older: a systematic analysis of data from GLOBOCAN 2022 and GBD2021.
Article in BMC geriatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Global Landscape of Colorectal cancer Incidence and Mortality in 2022 and Projections to 2045: New Estimates From GLOBOCAN 2022.Journal of gastrointestinal cancer · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUpdated and comprehensive global assessments of cancer statistics specifically targeting adults aged ≥ 60 years have remained limited. To address this gap, we conducted a systematic epidemiological analysis of cancer burden in this rapidly growing demographic worldwide.
methodsPopulation-based data from the Global Cancer Observatory (GLOBOCAN) 2022 and the Global Burden of Diseases (GBD) 2021 were used and analyzed in this study. The main outcomes of this study were age-standardised incidence (ASIR) or mortality rate (ASMR), and average annual percent change (AAPC). A Bayesian age-period-cohort model was employed to project cancer trends through 2050.
resultsGlobally, adults aged 60 years and older accounted for 65% of cancer diagnoses and 74% of cancer-related deaths in 2022. Among all cancer types, tracheal, bronchus, and lung (TBL) cancers had the highest incidence and mortality rates. Males and populations in high socio-demographic index (SDI) regions experienced a greater cancer burden compared to females and low-SDI populations. The ASIR and ASMR increased steadily with age, peaking in the over 85 age group. Geographically, ASIR was highest in the USA and Canada, followed by Australasia and Western Europe. Central Europe, East Asia, and Western Europe showed the highest ASMR. From 1992 to 2021, while both ASIR and ASMR declined globally, there were ongoing increases in the cancer burden for certain cancers, including breast, prostate, colorectal, pancreatic, and liver cancers. Projections indicate that, by 2050, the number of cases among this age group may rise to 22.2 million annually, with deaths possibly reaching 12.9 million. TBL cancers will remain the leading cause of cancer incidence and death, followed by breast cancer.
conclusionsThe global cancer burden among adults aged ≥ 60 years showed a pronounced heterogeneity across sex, age strata, geographic regions, and SDI levels, and will suffer a sustained increase over the coming decades. Our study offers a comprehensive epidemiological overview for prioritizing precision interventions targeting high-risk populations and policy formulation for aging societies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.